Literature DB >> 2615197

Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism.

E Slatopolsky1, C Weerts, K Norwood, K Giles, P Fryer, J Finch, D Windus, J Delmez.   

Abstract

Many investigators have shown that calcium carbonate (CaCO3) is an effective phosphate binder which also prevents the potential disabling effects of aluminum (Al) accumulation. However, hypercalcemia may develop in a substantial numbers of patients. Thus, to control serum phosphate (PO4) and prevent hypercalcemia, we performed studies in 21 patients on maintenance hemodialysis in which, in addition to the oral administration of CaCO3, the concentration of calcium (Ca) in the dialysate was reduced from 3.25 to 2.5 mEq/liter. The studies were divided in three periods: I. control, on Al-binders (one month); II. no Al-binders (one month); III. CaCO3 (seven months). Blood was obtained three times/week before dialysis for the first five months of the study and once a week for the remaining four months. During the control period, the mean serum calcium was 8.86 +/- 0.08 mg/dl. The value decreased to 8.65 +/- 0.07 mg/dl when phosphate binders containing aluminum were discontinued, and increased to 9.19 +/- 0.07 mg/dl (P less than 0.001 compared to period II) during oral supplementation with calcium carbonate. The mean serum phosphorus was 5.03 +/- 0.07 mg/dl during the control period, and increased to 7.29 +/- 0.91 mg/dl (P less than 0.001) after phosphate binders were discontinued. It decreased to 4.95 +/- 0.06 mg/dl (P less than 0.001) with the administration of calcium carbonate. During CaCO3 administration, serum Al decreased from 64.2 +/- 8.5 to 37.1 +/- 3.6 and 25.1 +/- 3.0 micrograms/liter (P less than 0.001) at three and seven months, respectively. Serum parathyroid hormone (PTH) decreased by 20%.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2615197     DOI: 10.1038/ki.1989.277

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  8 in total

Review 1.  Hyperphosphataemia in renal failure: causes, consequences and current management.

Authors:  Fouad Albaaj; Alastair Hutchison
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  Nephrology, dialysis and transplantation.

Authors:  K Farrington; P Sweny
Journal:  Postgrad Med J       Date:  1990-07       Impact factor: 2.401

Review 3.  Minimizing bone abnormalities in children with renal failure.

Authors:  Helena Ziólkowska
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 4.  Hyperphosphataemia: treatment options.

Authors:  Fabio Malberti
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

Review 5.  Management of musculoskeletal complications in endstage renal disease: an update.

Authors:  Dharmarajan Ramaswamy; Petros Efthimiou; Isaiarasi Gnanasekharan; Anita Soni
Journal:  Clin Rheumatol       Date:  2005-11-03       Impact factor: 2.980

6.  Calcium carbonate as a phosphate binder in dialysis patients: evaluation of an enteric-coated preparation and effect of additional aluminium hydroxide on hyperaluminaemia.

Authors:  T H Ittel; C Schäfer; H Schmitt; U Gladziwa; H G Sieberth
Journal:  Klin Wochenschr       Date:  1991-01-22

7.  Effects of low dialysate calcium concentration on health-related quality of life in hemodialysis patients.

Authors:  Yoshinori Taji; Takeshi Morimoto; Shunichi Fukuhara; Tsuguya Fukui; Takashi Kuwahara
Journal:  Clin Exp Nephrol       Date:  2005-06       Impact factor: 2.801

Review 8.  Safety of new phosphate binders for chronic renal failure.

Authors:  Mahmoud Loghman-Adham
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.